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Introduction
Immunotherapy with immune checkpoint inhibitors (ICIs) has 
achieved a remarkable improvement in overall survival (OS) in 
different tumor histologies, albeit the majority of patients display 
intrinsic resistance (1). The response to programmed cell death 
protein 1 (PD-1) blockade requires a preexisting and flourishing 
immune response and involves determinants of adaptive immuni-
ty, such as a high number of tumor DNA mutations or neoantigens, 
the interspersed distribution of infiltrating effector T cells, a high 
level of the expression of PD-L1, or an IFN-related gene signature 
(2, 3). In contrast, resistant tumors lack signs of immunogenic-
ity and are definable as “immune-desert” based on the absence 
of local T cell reactivity (4). Resistant tumors are also endowed 
with the innate anti–PD-1 resistance signature (IPRES) (5), which 
involves specific genetic programs, including wound healing, 
epithelial-mesenchymal transition (EMT), extracellular matrix 
remodeling, TGF-β signaling, hypoxia, macrophage chemotaxis, 
and angiogenesis. Most of these mirror the transcriptional pro-
file of myeloid-derived suppressor cells (MDSCs), a population 
of immature myeloid cells (IMCs) pathologically associated with 
cancer and known for their potent inhibitory activity on antitu-
mor T cell immunity (6). In addition, MDSCs directly coordinate 
cancer cell plasticity, triggering the EMT phenotype (7, 8) and acti-
vating signaling pathways often associated with drug resistance, 
stroma remodeling, and angiogenesis (9, 10). MDSCs distribute 
systemically in cancer patients, accumulating in the peripheral 
blood, lymph nodes (LNs), and distant organs, where they facili-
tate cancer dissemination by forming the so-called premetastat-
ic niche (6). A high frequency of MDSCs in the peripheral blood, 
mainly comprising monocytic and polymorphonuclear subsets (9, 
11), is associated with poor prognosis (6, 12) and represents a pos-
sible mechanism of resistance to immunotherapies (11, 13–17).
MDSC generation is believed to stem from conditioning of 
the BM by soluble tumor factors, including granulocyte-macro-
phage CSF (GM-CSF), macrophage CSF (M-CSF), granulocyte 
CSF (G-CSF), and other proinflammatory cytokines (6). A delivery 
of tumor factors could be facilitated by shuttling organelles (18). 
Extracellular vesicles (EVs), nanoparticles abundantly secreted by 
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M-MDSCs as CD11b+CD33+ myeloid cells expressing the hallmark 
CD14+HLA-DRneg phenotype and exerting immunosuppressive 
activity on T cells (9, 11). In an attempt to mimic this phenotype 
in vitro, we opted to use tumor EVs to convert normal myeloid 
cells. EVs were purified by differential centrifugation of condi-
tioned medium (CM) from melanoma cell lines and evaluated for 
their morphology and marker profiles (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI98060DS1). Here, we report that CD14+ 
monocytes, when exposed for 24 hours to melanoma EVs isolated 
from short-term (INT12, LM38) and long-term (Mel501, 624.38) 
cultured cell lines, show downregulated HLA-DR expression and 
cancer cells, are involved in the intercellular transfer of proteins, 
lipids, and genetic material, such as RNAs and microRNAs (miRs) 
(19–21). Because of their ability to recirculate in body fluids, EVs 
represent an ideal candidate in the process of BM conditioning 
that leads to MDSC generation (22, 23). In the present work, we 
identified a panel of circulating miRs associated with monocytic 
MDSC (M-MDSC) activity in melanoma patients, representing a 
potential tool to assess the role of these cells in resistance to ICIs.
Results
The monocyte-MDSC transition is mediated by melanoma EVs. We 
and others have previously defined cancer-associated human 
Figure 1. Conversion of myeloid cells into MDSCs by melanoma EVs. (A) HD-CD14+ cells (Mono) incubated 24 hours with melanoma EVs (Me EVs) downregulate 
HLA-DR (left, representative plot and summary of n = 7 HD), increase production of cytochemokines (middle), modulate HLA-DRA, IL6, and CCL2 gene transcrip-
tion (right), and (B) suppress proliferation of activated CFSE-labeled T cells (percentage proliferation indicated). (C) CD14+HLA-DRneg cell frequency and HLA-DR 
expression on gated CD14+ cells in PBMCs of melanoma patients (Pts, n = 31) and HD (n = 15) by flow cytometry. (D) HLA-DRA downregulation of HD (n = 5) and 
patients’ (n = 4) monocytes cultured with melanoma EVs. (E) Induction of EV-MDSCs in CD14+ cells from a patient by autologous melanoma cell line EVs (left); 
suppressive activity on activated CD25+ T cells (percentages indicated, right). (F) NTA evaluation of EV size in plasma samples of patients and HD (n = 27/group) 
(top); correlation of EV mean size and frequency of CD14+HLA-DRneg in gated CD14+ cells of melanoma patients (bottom). (G) EV-MDSC converting potential of 
f1 and f2 plasma EVs from patients and HD (n = 5/group) shown as HLA-DRA downregulation in monocytes from 2 different HD; control: melanoma EVs. Data 
are presented as mean ± SEM. (H) Autologous (auto) plasma EVs f1 and f2 convert melanoma patient’s CD14+ cells, as shown by modulation of HLA-DRA, IL6, 
and CCL2 transcripts (top). EV-MDSCs generated with autologous plasma EVs f1 and f2 of melanoma patient inhibit T cell proliferation (percentages indicated, 
bottom). (I) Western blot of plasma EV fractions (f1, f2) of HD and patient. gMFI, geo mean fluorescence intensity; RE, relative expression. FC was by using as 
calibrator untreated monocytes. P < 0.001 (A, right; E); P < 0.01 (A, left); P < 0.05 (H, top), paired Student’s t test. P < 0.05, Mann-Whitney U test (D). *P < 0.05, 
***P < 0.001, unpaired Student’s t test (C, F). Data are representative of 2 (E, H, I) and 3 (A, B) experiments.
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we could ascertain the induction of functional EV-MDSCs in an 
autologous setting, i.e., with EVs purified from CM of a patient’s 
melanoma cell line, which we incubated with the patient’s mono-
cytes isolated from PBMCs; these EV-MDSCs were able to inhibit 
autologous T cell proliferation (Figure 1E).
Parallel experiments have been performed in a murine 
setting with EVs released by the Ret melanoma cell line estab-
lished from skin melanomas developed by RET transgenic 
mice (ret-EVs) (26). ret-EVs converted BM IMCs into MDSCs 
in vitro, boosting NO, inducible NOS (iNOS), and arginase-I 
expression and immunosuppressive activity on T cell prolifera-
tion (Supplemental Figure 2, A–C). Upon i.p. administration to 
naive C57BL/6 mice, fluorescently labeled EVs interacted with 
Gr1+CD11b+ IMCs and, to a lesser extent, with F4/80+Gr1neg 
macrophages in the spleen, BM, and LNs (Supplemental Fig-
ure 2D). Repeated administration of ret-EVs led to a significant 
increase only in the frequency of Gr1+CD11b+Ly6Chi M-MDSCs, 
detectable in the BM (Supplemental Figure 2E).
increase of IL-6 and CCL2 transcription and secretion together 
with suppressive properties on activated T cells (Figure 1, A and B, 
and Supplemental Figure 1, B and C), a phenotype we have named 
EV-MDSCs. Monocyte conditioning strictly relies on the pres-
ence of vesicles, as EV-depleted melanoma CM loses the ability 
to downregulate HLA-DR expression (Supplemental Figure 1D).
CD14+HLA-DRneg M-MDSCs accumulate in the peripher-
al blood of metastatic melanoma patients, as compared with 
healthy donors (HD) (Figure 1C) (11, 24), and show spontaneous 
production of immunosuppressive and protumor factors, such as 
IL-6, CCL2, and TGF-β (10, 11, 25), detected ex vivo as RNA and 
proteins (Supplemental Figure 1E). Their suppressive potential is 
documented by the boost or decrease of T cell proliferation upon 
depletion or readdition of CD14+ cells from patients’ peripher-
al blood mononuclear cells (PBMCs) (Supplemental Figure 1F). 
Interestingly, CD14+ cells from patients retain the potential to 
acquire EV-MDSC features, measured as HLA-DRA downregula-
tion in the presence of melanoma EVs (Figure 1D). Furthermore, 
Figure 2. Transcriptional regulation of EV-MDSCs at the gene level. (A) Heatmaps of the genes regulated in EV-MDSCs (+EVs) compared with untreated 
monocytes (Mono, n = 5 HD) clustered according to the most representative functional categories. (B) EMT-related genes selected by a list of 839 genes 
from melanoma IPRES, EMT, and wound healing (5); from the literature-based EMT database (32); and from mesenchymal myeloid markers (33). (C) The 
FC of expression levels of selected genes in EV-MDSCs compared with untreated monocytes measured by qPCR. P < 0.01, paired Student’s t test. A repre-
sentative HD of 5 tested from part A is shown. (D) GSEA plots obtained with the top 100 upregulated genes in EV-MDSCs showing a significant enrichment 
in data sets comparing the transcriptomic profiles of blood monocytes from colorectal, pancreatic, and breast cancer patients to those of monocytes 
obtained from HD. GSE47756, colon cancer (37); GSE60601, pancreatic cancer (38); GSE65517, metastatic breast cancer (39).
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tant at 118,000 g), as indicated by transmission electron 
microscopy (TEM) and bead-calibrated flow cytometry 
(Supplemental Figure 3B). Interestingly, f1 EVs from 
melanoma patients’ plasma downregulated HLA-DRA at 
RNA levels in HD CD14+ monocytes upon in vitro cocul-
ture, suggesting the presence of EV-MDSC–converting 
vesicles potentially derived from tumor cells (Figure 1G). 
This effect was less frequent with f2 EVs from melanoma 
patients, which, in contrast, induced an increase of HLA-
DRA expression in HD monocytes. The upregulation of 
HLA-DRA at the RNA level could be ascribed to monocyte 
activation, possibly due to the presence of stimulating EVs 
in f2 plasma fractions, likely originating from antigen-pre-
senting cells (APCs), similarly to what we observed with 
f1 and f2 from plasma of HDs (Figure 1G). Reports have 
indeed shown that plasma exosomes can activate mono-
cytes by inducing the upregulation of HLA-DR and CD86 
expression in healthy and pathological conditions (27, 28).
Similarly to normal monocytes, monocytes from 
melanoma patients downregulated their HLA-DRA 
expression upon coculture with autologous plasma f1 and 
f2 EVs, accentuating the potential relevance of this phe-
nomenon in vivo. Of note, EV-MDSCs generated with autologous 
plasma f1 and f2 EVs displayed an increased suppressive effect on 
T cell proliferation with respect to unconditioned monocytes (Fig-
ure 1H). The actual presence of melanoma EVs in patients’ plasma 
could be confirmed by protein analysis, showing that, in contrast 
with HD, both f1 and f2 EVs of the patient expressed the gp100 
melanoma marker, with a tendency to accumulate in f1. These 
data may contribute to explaining the downregulation of HLA-
DRA in HD monocytes that we observed predominantly with f1 
plasma EVs from melanoma patients, as shown in Figure 1G. An 
increase in f1 could also be assessed for the EV markers Rab5B, 
CD63, and CD49b/VLA-2 integrin, while both fractions showed 
similar levels of the LAMP-2 EV marker (Figure 1I).
Since tumor EVs can circulate in body fluids together with EVs 
originating from immune and other cells, we tested to determine 
whether plasma EVs from advanced melanoma patients could also 
promote the EV-MDSC phenotype in vitro. EV screening of unpro-
cessed plasma by nanoparticle tracking analysis (NTA) showed 
that patients’ samples contained EVs in increased numbers and 
mean sizes as compared with those from HDs. Notably, the size of 
EVs directly correlated with the frequency of circulating MDSCs in 
matched peripheral blood samples, suggesting a potential link to the 
disease (Figure 1F and Supplemental Figure 3A). To obtain vesicles 
for functional studies, we applied a 2-step centrifugation protocol 
aimed at enriching for larger (f1, obtained at 16,500 g) versus small-
er EVs (f2, obtained with subsequent centrifugation of f1 superna-
Figure 3. miR regulation in EV-MDSCs. (A) Volcano plot of the 
miRs regulated in EV-MDSCs (n = 5 HD) compared with untreat-
ed monocytes based on microarray results, identification strat-
egy of MDSC-miRs, and relative expression of selected miRs in 
EV-MDSCs compared with untreated monocytes assessed by 
qPCR in a representative HD. (B) Expression of MDSC-miRs in 
f1 and f2 plasma EVs of melanoma patients (n = 16). Box and 
whiskers (Tukey’s test). (C) Monocytes from HD transfected 
with MDSC-miR mimics (MmiRs) modulate HLA-DRA, IL6, and 
CCL2 gene expression compared with monocytes treated with 
scrambled control used as calibrator. (D) Immunosuppressive 
activity of mono+MmiRs on autologous activated CFSE- labeled 
T cells, as evaluated by CD25 expression and proliferation 
(percentage is indicated, left), and release of IFN-γ and TNF-α 
(right). (E) Loss of immunosuppressive activity of monocytes 
from a melanoma patient transfected with miR inhibitors 
(ImiRs) prior to coincubation with autologous activated 
CFSE-labeled T cells, as evaluated by flow cytometry (left) and 
cytokine release (right). (F) Expression of MDSC-miRs in CD14+ 
cells isolated from PBMCs of melanoma patients (n = 31) and HD 
(n = 15). AU, arbitrary units. P < 0.05, paired Student’s t test (A, 
C) and Mann-Whitney U test (F). *P < 0.05; **P < 0.01, paired 
Student’s t test (B, D,  E). Results are representative of 5 (C), 4 
(D), and 3 (E) experiments.
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ing CCL1, CCL22, CXCL5, CCL7, CSF1, and PPBP/CXCL7, among 
the top hits. Several transcriptional factors were upregulated, 
including HIF1, mTOR, NOTCH1, NFKB2, RUNX1, MYC, ETS1, 
factors involved in STAT3 downstream signaling pathways (MYC, 
CCND1, and MCL1), and different SMAD genes, most of which 
have been reported to be involved in MDSC functions (29–31). 
Genes involved in increased survival and antiapoptotic effects 
(e.g., BCL2 and CDKN2A) were enhanced, together with some 
molecular hallmarks of murine MDSCs, including S100A8 and 
MMP9 (Figure 2A). Notably, approximately 10% of genes differ-
entially expressed in EV-MDSCs were associated with EMT, as 
revealed by analysis of the overlap in a list of EMT-related genes; 
this analysis included an EMT database (32), gene sets associated 
with EMT and/or wound healing in the IPRES signature (5), and 
genes common to mesenchymal and myeloid cells (33) (Figure 
The transcriptional regulation of EV-MDSCs involves miR 
modulation. We next investigated the molecular mechanisms 
leading to the in vitro induction of EV-MDSCs. Genome-wide 
transcriptional analysis revealed 662 genes, 514 upregulated 
and 148 downregulated (fold change [FC]>|2|, FDR < 0.05), as 
differentially expressed in EV-MDSCs with respect to untreated 
monocytes (Supplemental Table 1). Gene Ontology (GO) enrich-
ment analysis indicated that most of the upregulated genes were 
involved in various immune cell functions, including inflamma-
tory response, apoptosis signaling pathways, signal transduction 
regulation, and wound healing (Supplemental Table 2). Notably, 
the expression pattern of bona fide MDSC hallmark genes in the 
human setting is detectable in EV-MDSCs at the transcriptional 
level. We also identified key chemokines for protumor myeloid 
cell functions and hematopoietic stem cell maintenance, includ-
Figure 4. Inhibition of MDSC-miRs rescues monocytes from the acquisition of a suppressive phenotype. (A) Effect of transfection with miR inhibitors 
or scrambled control (Scr) on MDSC-miR expression in INT12 melanoma cells and respective EVs (left panel). Reduced expression of miR-146a in silenced 
melanoma cells (Me) was confirmed by flow cytometry using an APC-fluorescent SmartFlare probe (right panel). (B) EVs derived from miR-silenced 
melanoma cells (+I-EVs) impaired the induction of the EV-MDSC phenotype compared with EVs derived from scrambled control cells (+S-EVs) (left panel); 
MDSC-miR expression was reduced in monocytes treated with I-EVs compared with those treated with S-EVs (right panel). (C) Effect of transfection with 
miR inhibitors or scrambled control of HD monocytes cultured in the presence of melanoma EVs, as evaluated by qPCR and flow cytometry, and (D) IL-6 
and CCL2 release. (E) Loss of immunosuppressive activity of EV-MDSCs, generated from HD in the presence of miR inhibitors or scrambled control, on 
activated CFSE-labeled T cells, as evaluated by flow cytometry (left panel) and cytokine release (right panel), and (F) loss of immunosuppressive activity 
of EV-MDSCs generated from a patient with autologous melanoma–derived EVs. Percentages of CD25 and CFSE expression are indicated. Cells transfected 
with scrambled control were used as a calibrator (A–C). P < 0.05, paired Student’s t test (A–C); P < 0.001, 1-way ANOVA (D). *P < 0.05, **P < 0.01, paired 
Student’s t test (E, F). Experiments were repeated twice and performed in triplicate (A–D, F). Data are representative of 2 HD tested (E).
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2B). The modulation of critical genes, including the downregu-
lation of HLA-DRA, HLA-DPA1, CD1D, and TLRs (TLR4, TLR5, 
TLR7) and the upregulation of CD274/PD-L1, TNFRSF8/CD30, 
genes promoting angiogenesis and metastasis (PTGS2 and VEG-
FA), and genes controlling cell survival and proliferation (BCL2A1 
and CDKN2A), have been confirmed by quantitative real-time 
PCR (qPCR) analysis (Figure 2C).
The CIBERSORT assessment of transcriptome data (34) 
shows a significant enrichment of the M0 fraction of nonpolarized 
monocytes (Supplemental Figure 4) rather than M1 and M2 polar-
ized macrophage fractions (35). In silico analysis of EV- MDSC–
regulated genes also indicated a consistent overlap with an MDSC 
gene list described in colon tumor tissue data sets (36). To con-
firm the overlapping features of our EV-MDSCs with myeloid cells 
from cancer patients, we compared the transcriptomic profile of 
EV-MDSCs with those of monocytes sorted from the blood of 
patients with different tumor types (37–39) and found a significant 
enrichment of the overexpressed genes (Figure 2D).
Monocyte skewing to EV-MDSCs also showed changes in 
miR expression. Via profiling, 98 miRs were identified as dif-
ferentially expressed between monocytes and EV-MDSCs (FC 
|1.2|, FDR < 0.05); 34 were differentially expressed, with a FC of 
≥|2|, including miRs, such as miR-146a, miR-125, and miR-155, 
described as being involved in the regulation of classical and 
alternative myeloid cell activation (Figure 3A and Supplemental 
Table 3) (40–42). Integrative analysis of miRs and gene expres-
Figure 5. MDSC-miRs are expressed in tumor specimens and monocytes of melanoma patients. (A) Correlation matrix of the expression levels of MDSC-miRs 
and CD163, CD14, CD209, ITGAM, CD33, CD68, CD3D, CD4, CD8A, PMEL, TYR, and MLANA in metastatic melanoma specimens (n = 58); PMEL, TYR, MLANA, 
miR-21, and miR-211 are used as unrelated controls. r values from univariate Spearman’s analysis in correlations with P < 0.05. (B) Immunostaining of CD163 
infiltrate in melanoma (left panel) and correlation of the quantified CD163 signal with the expression levels of MDSC-miRs (right panel), as determined by 
qPCR (n = 20). (C) ISH images showing the expression of miR-146a, miR-100, miR-125b, and miR-155 in representative tumor sections. miR signals appear as 
brown dots localized both in CD163+ infiltrating cells and in melanoma cells. Scale bars: 100 μm. Representative images are shown in B and C.
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sion profiling data revealed regulatory networks governing key 
myeloid cell functions, including the chemotaxis, adhesion, dif-
ferentiation, and recruitment of phagocytes, macrophages, and 
APCs (Supplemental Figure 5).
miRs induce the EV-MDSC phenotype in CD14+ monocytes. 
Since EVs are known miR carriers (43–45), we hypothesized that 
EV- mediated miR cargo is involved in the process of in vitro 
EV-MDSC conversion. Profiling enabled us to identify 104 miRs 
detectable in both melanoma EVs and matched tumor cells (Sup-
plemental Table 4). By crossing this set of miRs with those overex-
pressed in EV-MDSCs and associated with gene downregulation, 
we selected the top upregulated miRs — namely, miR-146a, miR-
155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, and miR-
99b — as MDSC-associated miRs for subsequent studies (Figure 
3A; Supplemental Table 5). The evaluation of these miRs in plas-
ma EV fractions f1 and f2 of melanoma patients showed that they 
were all detectable and that 5 out of 8 miRs (miR-146a, miR-146b, 
let-7e, miR-99b and miR-125b) were enriched in the f1 EV fraction, 
while the others appeared equally distributed (Figure 3B). Similar-
ly, melanoma cell line–derived EVs showed comparable levels of 
MDSC-miRs in f1 and f2, compatible with the release of larger and 
smaller EVs by melanoma cells in vitro. Of note, the miR content 
associated with the induction of EV-MDSCs, as shown by HLA-
DRA downregulation in HD monocytes (Supplemental Figure 6). 
The contribution of MDSC-miRs in MDSC conversion was then 
explored with the help of corresponding mimics transfected into 
HD monocytes. Similarly to EV-MDSCs, miR-transfected mono-
cytes displayed downregulation of HLA-DRA and the induction 
of IL6 and CCL2 expression (Figure 3C). In line with their MDSC 
nature, these cells also exerted suppressive activity on T cells, 
as suggested by the impairment of proliferation, CD25 expres-
sion, and IFN-γ and TNF-α secretion in T cell receptor–triggered 
(TCR-triggered) autologous T cells (Figure 3D). Conversely, the 
transfection of melanoma patient–derived monocytes with miR 
inhibitors led to their functional recovery (Figure 3E), indicating 
that MDSC-miRs play a role in sustaining myeloid cell–related 
protumor effects. The potential link of MDSC-miR expression and 
the accumulation of MDSCs in melanoma patients’ peripheral 
blood was also supported by a significantly higher expression of 6 
out of 8 MDSC-miRs in the patients’ samples, which we observed 
upon comparing the levels of MDSC-miRs in CD14+ cells sorted 
from PBMCs of HD with those of metastatic stage IIIC–IV mela-
noma patients at treatment baseline (i.e., at ≥ 1 month apart from 
any systemic therapy) (Figure 3F).
We next assessed the contribution of direct MDSC-miR trans-
fer from a tumor to monocytes via EVs with the aid of EVs derived 
from melanoma cells silenced for miR-146a, miR-100, miR-125b, 
and miR-155. miR-devoid EVs lost the ability to convert mono-
cytes into EV-MDSCs in terms of HLA-DRA downmodulation, 
CCL2 and IL6 induction, and MDSC-miR upregulation (Figure 
4, A and B). Similarly, the contemporaneous inhibition of these 
MDSC-miRs by adding miR inhibitors to melanoma EV–exposed 
monocytes from HD abrogated the acquisition of the EV-MDSC 
phenotype as well as suppressive activity on T cell activation and 
cytokine production (Figure 4, C–E). Of note, the addition of miR 
inhibitors to a patient’s monocytes conditioned with EVs deriving 
from the autologous melanoma cell line also restored T cell activi-
ty and cytokine release (Figure 4F).
Taken together, these results show that MDSC-miRs dis-
play an increased expression in monocytes of patients, circulate 
within EVs in patients’ plasma, and condition myeloid cells via 
EV-mediated transfer.
Figure 6. MDSC-miRs are enriched in plasma from melanoma patients and associate to resistance to immunotherapy. (A) MDSC-miR detection in 
the plasma of patients (Pts) and HD (n = 20/group). miR expression levels were normalized using ath-miR-159a as reference miR. RE, relative expres-
sion. *P < 0.05; **P < 0.01, Mann-Whitney U test. (B) OS of metastatic melanoma patients based on the expression levels of MDSC-miRs in plasma 
samples obtained at baseline of therapy, assessed by multivariable index score approach and AIM, in the global population (n = 87; left panel) and in 
the subsets of patients receiving immunotherapy (ICIs, n = 49) or targeted therapy (TKIs, n = 37). One patient was excluded from the latter because of 
receiving chemotherapy. Patients with low scores (0–1; showing 0 or only 1 increased miR) had a significantly better OS compared with patients with 
high scores (>1; having 2–5 increased miRs) only if receiving ICIs. Kaplan-Meier survival curves with log-rank P values are shown.
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than were the high scores (Figure 6B). A comparable trend was 
observed when PFS was analyzed (Supplemental Figure 8). Most 
importantly, when these data were divided by the type of therapy, 
the difference in OS between low and high scores was much more 
evident, with a P value of 0.003, for ICI-treated patients; no differ-
ence was detected for TKI-treated patients. Comparable data were 
observed for PFS; however, the curves for ICI patients were less 
divergent than were those for OS due to the known minor impact 
of ICIs on PFS (2). These data clearly indicate that our MDSC-
miRs may represent predictive markers of the response to or the 
benefit of ICIs in advanced melanoma patients.
Discussion
In the present work, we discovered a set of miRs that associates 
with the phenotypic and functional features of M-MDSCs in mel-
anoma patients. These miRs are detected in plasma as associated 
with EVs, in blood monocytes, and in tumor biopsies, as correlat-
ed with the frequency of altered myeloid cells. Most importantly, 
higher circulating levels of these miRs cluster with shorter PFS 
and OS in patients receiving ipilimumab and nivolumab, but not 
in those treated with BRAF/MEK inhibitors. These latter findings, 
if prospectively validated, pave the way for the development of 
what, to our knowledge, represents the first predictive peripheral 
blood biomarker of resistance to ICIs in cancer. The assessment of 
MDSC-miRs would make use of the concept of liquid biopsy (46), 
which has traditionally focused on genetic tumor features (47), but 
surely could be implemented with information from the systemic 
environment, including host immunity (48).
The evidence that factors associated with myeloid-related 
immune suppression might influence disease outcome in mela-
noma patients is not unexpected, as higher MDSC frequency is 
a constant in poor disease prognosis, even during ICI adminis-
tration (14–17). The true predictive role of the MDSC-miRs here 
identified might instead reflect specific functional properties 
that MDSCs could exhibit once immune responses are unleashed 
by the ICIs (29). This hypothesis is in line with preclinical data 
showing that tumor resistance to PD-1 or CTLA4 blockade can be 
reverted by myeloid cell depletion (49, 50).
Major evidence, albeit primarily in murine models, indicates 
a central role of miR-mediated posttranscriptional regulation in 
MDSC differentiation and function (40, 51). Via in vitro studies 
on monocyte conditioning, we found that hallmarks of human 
MDSCs, i.e., downregulation of HLA-DR, secretion of IL-6, 
TGF-β, and CCL2, and inhibition of T cell proliferation and func-
tion (9, 10), can be reconstituted by in vitro cotransfection of the 
8 MDSC-miRs; this finding held true even when the requirement 
was decreased to 4 miRs (miR-146a, miR-100, miR-125b, and 
miR-155) in some donors (data not shown). The chance of cap-
turing such a complex regulatory scenario likely stems from the 
use of tumor EVs for MDSC generation. Indeed, EVs are known 
to carry distinct sets of miRs and to deliver them into target cells 
for the induction of specific functions, a key mechanism of inter-
cellular crosstalk (52). In the context of cancer, transformed cells 
exploit EV-mediated miR transfer to mold host tissues by trigger-
ing angiogenesis, EMT, invasion and metastasis, immune escape, 
and multidrug resistance (23, 43). Here, we provide experimen-
tal proof that melanoma EVs are embedded with a set of miRs 
MDSC-miRs are enriched in correlation with myeloid cell accrual. 
The relevance of MDSC-miRs was next investigated ex vivo in 
human melanoma specimens. As expected, we detected high miR-
146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, 
and miR-99b levels in subcutaneous, visceral, and LN metastases 
from stage III–IV melanoma patients (n = 58) by qPCR, confirm-
ing the expression of these miRs by this tumor type (Supplemen-
tal Figure 7). Interestingly, MDSC-miRs correlated with myeloid 
markers CD163, CD14, CD209, CD68, ITGAM (CD11b/Mac-1), 
and CD33 detected in the same samples, but not with T cell mark-
ers CD3, CD4, and CD8 or with tumor-related markers PMEL, 
TYR, MLANA, miR-21, and miR-211; the only exceptions were 
miR-155 and miR-100, which correlated with CD4 (Figure 5A and 
Supplemental Table 6). Multivariate statistical analysis showed 
a significant correlation between the MDSC-miR cluster and the 
expression of all myeloid markers (P = 0.0062, r = 0.5491). Addi-
tionally, the correlation of CD14 and CD163 expression with the 
miR-146a, miR-100, miR-125b, and miR-155 clusters was also sig-
nificant (P = 0.0455, r = 0.2088). The association of MDSC-miRs 
with infiltrating myeloid cells at the RNA level was confirmed by 
the correlation of miR-146a, miR-125b, and miR-146b with the 
number of CD163+ cells in tumor sections (Figure 5B). Indeed, in 
situ hybridization revealed that miR-146a, miR-100, miR-125b, 
and miR-155 expression was localized in both CD163+ and mela-
noma cells (Figure 5C). These data suggest that these miRs might 
be indicators of MDSC activity at the tumor site.
MDSC-miRs are enriched in the plasma of melanoma patients 
and cluster with resistance to immunotherapy. To assess MDSC-
miRs in the circulation, we measured their expression levels in 
plasma obtained from melanoma patients with advanced disease 
(stage IIIC unresectable and stage IV) (n = 20) and from a group of 
age- and sex-matched HD (n = 20). The analysis showed increased 
levels of all MDSC-miRs in the patients, with statistically signifi-
cant differences shown for miR-146a, let-7e, miR-125a, and miR-
146b (Figure 6A). Notably, the expression levels of the studied 
miRs appeared more intercorrelated in patients than in HD (data 
not shown), further indicating an association with disease.
To test the potential for using MDSC-miRs as peripheral 
blood–based markers, we conducted a retrospective analysis in 
a set of plasma samples obtained from metastatic melanoma 
patients (n = 87) receiving either ICIs (ipilimumab or nivolum-
ab) or targeted therapy (tyrosine- kinase inhibitors [TKIs]; 
vemurafenib or the combination of dabrafenib and trametinib). 
Enrolled patients included 49 and 37 patients in the ICI and TKI 
groups, respectively (Supplemental Table 7). The expression levels 
of MDCS-miRs in the baseline samples were analyzed and cor-
related with OS and progression-free survival (PFS), both singly 
and jointly, in the latter case via a machine learning tool known as 
adaptive index modeling (AIM). By estimating the joint contribu-
tion of the 5 miRs showing an association with disease outcomes 
in univariable assessments (let-7e, miR-125a, miR-99b, miR-146b, 
and miR-125b), we were able to divide patients into 5 groups on the 
basis of an index score comprising the number of miRs showing 
increased expression, as detailed in Methods. Regarding OS, by 
pooling low scores (0–1; consisting of 0 or only 1 increased miR) 
versus high scores (>1; having 2 to 5 altered miRs), we observed 
that the low scores were associated with significantly better OS 
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els holds promise as a potential biomarker to assess and monitor 
systemic immunosuppression in cancer patients, possibly predict-
ing their chance of responding to ICIs.
Methods
Human studies. Peripheral blood samples from fasting patients and 
HD were processed within 2 hours for plasma collection and PBMC 
isolation and storage (11). PBMCs from stage III–IV patients obtained 
before surgery or medical treatment were studied for MDSCs by 
immunophenotyping, and sorted CD14+ cells were assayed for cyto-
kine, miR expression, and MDSC conversion and suppressive func-
tion. Plasma from stage IIIC–IV patients at baseline prior to any med-
ical treatment was studied for circulating EVs and miRs. Metastatic 
tumor specimens obtained from stage IIIC–IV melanoma patients 
were snap-frozen and processed for RNA extraction and analyses.
Mouse studies. C57BL/6 mice were purchased from Charles River 
Laboratories. In vivo and ex vivo interaction studies investigating the 
effects of ret melanoma EVs on myeloid cells involved the i.p. injection 
of 200 μg EVs, labeled with Cell Proliferation Dye eFluor 670 (Thermo 
Fisher Scientific) for interaction, or unlabeled EVs injected 3 times every 
48 hours. Four days after the last injection, the animals were sacrificed to 
collect the BM and spleen cells for flow cytometry evaluation. CD11b+Gr1+ 
IMCs (105) were cultured with 5 μg EVs overnight. NO production was 
measured by Griess Reagent (Promega), and arginase-I and iNOS expres-
sion were measured by flow cytometry. Treated IMCs were washed twice 
by centrifugation to remove EVs and coincubated with CFSE-labeled T 
cells stimulated with CD3/CD28 mAbs (T cells/IMCs = 1:1).
Cell cultures. Melanoma cell lines were generated in our laboratory 
from human melanoma specimens (71). The ret mouse melanoma cell 
line was established from the skin tumors of ret transgenic mice (26). 
Mycoplasma contamination was tested periodically.
Isolation of EVs. According to a standardized protocol optimized 
for large-scale EV production, the supernatant of 109 human melano-
ma cells, cultured for 72 hours in RPMI 1640 medium containing 10% 
EV-depleted FCS (obtained by centrifuging FCS 2 hours at 118,000 g), 
2 mM l-glutamine, and 200 U/ml penicillin/streptomycin, was cen-
trifuged at 300 g for 10 minutes, 0.22 μm vacuum filtered (Millipore), 
and ultracentrifuged (Sorvall WX Ultra 100, Thermo Fisher Scientific) 
at 100,000 g for 2 hours at 4°C. Subsequently, collected EVs were sus-
pended in PBS and washed by ultracentrifugation (1 hour, 118,000 g, 
4°C). After protein quantification (Bradford Protein Assay, Bio-Rad), 
aliquots were frozen at –80°C until further use. Ret murine melanoma 
EVs were purified from 48 hours serum-free CM of ret cells by sequen-
tial centrifugation (300 g for 10 minutes, 4,000 g for 20 minutes), 
0.22 μm vacuum filtering, and ultracentrifugation at 100,000 g for 4 
hours at 4°C. Further processing was analogous to the process for EVs 
from human melanoma cell lines. Plasma samples were obtained from 
EDTA blood samples after centrifugation at 3000 g for 10 minutes, 
followed by plasma centrifugation at 3000 g for 10 minutes. For EV 
isolation, 500 μl plasma diluted 1:8 times with 0.1 μm–filtered PBS 
was centrifuged at 16,500 g for 10 minutes to obtain the fraction 1 EV 
pellet, and the supernatant was centrifuged at 118,000 g for 1.5 hours 
to sediment the fraction 2 EVs. The same protocol was also applied to 
isolate f1 and f2 human melanoma EVs from CM.
NTA. The size distribution and concentration of EVs purified from 
CM of melanoma cells (5 μg diluted 1:10,000) and of EVs in unpro-
cessed plasma samples (5 μl diluted 1:10,000) or cell-depleted CM 
ready to convert monocytes into bona fide MDSCs upon direct 
transfer. As this process is mimicked by ret-EVs injected in vivo 
into C57BL/6 mice (Supplemental Figure 2E), it is reasonable 
to hypothesize that MDSC accumulation in melanoma patients 
might also involve in vivo myeloid conditioning by tumor EVs. 
The ability of these nanoparticles to distribute in body fluids (20) 
and reach the BM as well as other immunoregulatory sites could 
then account for the alteration of myelopoiesis, as depicted by our 
mouse studies as well as by previous preclinical data (18).
An in vitro tumor–mediated conversion of differentiated 
monocytes to MDSC-resembling cells was already reported by 
others (53). This process can be explained by the high plasticity of 
monocyte differentiation that cancer can arrest and shift toward 
immunoregulatory/suppressive mediators, as originally described 
for sepsis and cardiovascular diseases (54). This evidence sup-
ports the recently introduced hypothesis that cancer-associated 
myeloid dysfunctions could stem not only from progenitor condi-
tioning in the BM, but also from the peripheral reprogramming of 
circulating differentiated monocytes and neutrophils (55, 56).
Most of the miRs here identified are involved in myeloid 
cell differentiation and polarization by participating in path-
ways often associated with cancer-related immunosuppres-
sion (57–59). For instance, miR-146a, one of the most studied 
myeloid miRs (40), is reported to serve as negative feedback 
in the TLR4-mediated activation of NF-κB–related genes (60) 
and to promote M2 polarization in both humans and mice (42). 
miR-155, in addition to its key role in T cell responses (61), is the 
top upregulated miR in GM-CSF– and IL6-induced MDSCs and 
is involved in STAT3 activation via SHIP-1 and PTEN targeting 
(62). This miR has also been shown to facilitate tumor growth by 
promoting MDSC accrual, survival, and function through SOCS1 
inhibition (63–66). Similarly, miR-125b and miR-125a have been 
implicated in monocyte differentiation toward immunosuppres-
sive phenotypes (40, 42) via a pathway involving Lin28A (67), a 
key factor in hematopoietic stem cell growth and survival (68). 
miR-125b is produced with miR-100 from a common primary 
polycistronic transcript; miR-99b, let-7e, and miR-125a are pro-
duced via a similar mechanism (69), which explains their coor-
dinated expression in tumor biopsies and in circulating mono-
cytes from melanoma patients (Figure 5A and Figure 3F). The 
miR-99b/let-7e/miR-125a miR cluster was also shown to play a 
role in the mechanisms that stabilize STAT-3 activity in tolero-
genic APC (70). Specific insights into the pathways targeted by 
MDSC-miRs derive from matching their predicted gene panels 
with the transcriptional profile of EV-MSDCs, an analysis that 
provides key information about the vital processes of cancer-re-
lated myeloid dysfunctions involving chemotaxis, adhesion, and 
differentiation, with nodes including expected and previously 
unidentified patterns (Supplemental Figure 5).
Overall, our study sheds light on the poorly defined patterns 
of human MDSC activity, providing strong evidence about the 
role of defined miRs in driving cancer-related myeloid cell repro-
gramming. The involvement of MDSC activation and expansion 
in limiting the clinical efficacy of ICIs is also strengthened by our 
results, pointing to the need for drugs for the correction of myeloid 
dysfunctions (51) to overcome immunotherapy resistance in mel-
anoma patients. Finally, the evaluation of MDSC-miR plasma lev-
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miRNA Plasma Kit (Macherey-Nagel) was used for RNA isolation. 
250 μl of plasma were used. Before performing RNA extraction, EV 
samples were treated with RNAse A (10 μg/ml, Sigma-Aldrich) for 
1 hour at 37°C. miR expression levels were evaluated using Thermo 
Fisher reagents; a preamplification step was included in this process. 
To evaluate MDSC-miRs in the plasma of patients, RNA was reverse 
transcribed and preamplified with Megaplex RT and PreAmp Primers 
Human Pool A and tested in duplicate with TaqMan Array MicroRNA 
Cards (Thermo Fisher Scientific). To set up miRNA analysis by cus-
tomized cards, the system conditions relative to spike-in use, retro-
transcription, and preamplification conditions were defined in titra-
tion experiments and ath-miR-159a to control RNA extraction and U6 
snRNA were used for quality control. All samples were tested in the 
same batch of cards. The cards were run on QuantStudio 7 Flex, and 
analysis was performed with QuantStudio 6 and 7 Flex software.
Gene expression and miR microarray profiling. Gene expression pro-
files were generated using the HumanHT-12 v4 WGDASL BeadChip 
array (Illumina), and miR profiles were obtained using custom Sure-
Print Human miRNA Microarrays (Agilent). Raw gene expression data 
were log2 transformed and normalized with robust spline normaliza-
tion using the lumi package (73). Probes with a detection P value of 
less than 0.01 in at least 1 sample were kept, and for each gene, the 
probe with the highest detection rate was selected. Raw miR data were 
background corrected with the normexp method and quantile normal-
ized using the limma package (74). Only probes with intensity higher 
than 10% of the 95th percentile of the negative controls in at least 1 
sample were kept. The intensities of replicate probes were averaged, 
and the probes with the highest mean expression across samples were 
selected for each miR. Differential expression analysis was carried out 
with the limma package. P values were corrected for multiple testing 
using the Benjamini-Hochberg FDR. Genes and miRs with FDR of 
less than 0.05 and absolute FC of 1.2 or more were considered signif-
icant. All original microarray data were deposited in the NCBI’s Gene 
Expression Omnibus database (GSE102011). Functional analyses 
were generated through the use of IPA (QIAGEN Inc., https://www.
qiagenbioinformatics.com/products/ingenuity-pathway-analysis/) 
and Gene Set Enrichment Analysis (GSEA) (75). In silico evaluation of 
subpopulations was assessed with CIBERSORT (34).
IHC and ISH. Melanoma sections were stained for CD163 after 
antigen retrieval performed by heating in a pressure cooker with citrate 
buffer at pH 6, 5 mM for 15 minutes and using the Dako REAL Detec-
tion System Alkaline Phosphatase/RED kit and red AP as a chromogen 
(Dako Agilent). Sections were scanned using the Aperio ScanScope 
XT systems (Aperio Technologies, Leica Microsystems), and signal 
quantifications were conducted by image analysis by MIAQuant as 
described previously (76). ISH analysis for miR visualization was per-
formed by hybridization with double-DIG-LNA probes and positive 
and negative controls (Exiqon), as previously described (77). High-res-
olution Z stacks were acquired using Olympus BX63 equipped with a 
DP89 camera and cellSens software (Olympus).
Statistics. Data were analyzed using GraphPad Prism 5 and 7 
software (GraphPad Software Inc.). Unless otherwise indicated, the 
results are presented as mean ± SD and in box and whiskers plots; the 
box boundaries represent the 25th and 75th percentiles, the middle 
line is the median value, and the whiskers represent the minimum and 
maximum values. The results were analyzed using 2-tailed unpaired 
or paired Student’s t tests, Mann-Whitney U tests, and Pearson’s and 
of melanoma cells (dilution 1:2) were determined using an LM10-HS 
NanoSight instrument and evaluated with NTA software (Malvern 
Instruments). Preparations were analyzed 5 times for 30 seconds.
TEM. Freshly isolated plasma EV preparations were fixed with 4% 
paraformaldehyde and deposited on Formvar carbon-coated nickel 
grids. Grids were doubly stained with uranyl acetate and lead citrate 
and examined by TEM (CM 10 Philips; FEI).
Western blot analysis. Proteins obtained from purified EVs and cells 
were separated on 4% to 12% Bis-Tris precast gels (Invitrogen), trans-
ferred to nitrocellulose membranes (Amersham), and incubated with 
Abs. Reactive proteins were visualized using HRP-conjugated second-
ary Abs (Amersham) and enhanced chemiluminescence (Amersham, 
SuperSignal). The list of Abs used is provided in Supplemental Table 8.
Flow cytometry. To perform immunophenotyping studies, human 
and mouse cells were incubated with specific fluorochrome–conjugat-
ed Abs or isotype controls, provided in Supplemental Table 8, washed, 
and analyzed. Flow cytometry of EVs from melanoma cells was per-
formed using sulfate/aldehyde 5 μm latex beads (Thermo Fisher Sci-
entific) (72). A SmartFlare detection probe for miR-146a was used 
according to the manufacturer’s instructions (Merck Millipore). Sam-
ples were evaluated using a FACSCalibur (BD Biosciences) and a Gal-
lios or Cytoflex flow cytometer (Beckman Coulter) and FlowJo soft-
ware (TreeStar Inc.). Morphology of plasma EV fractions was assessed 
by acquisition with the Gallios flow cytometer (Beckman Coulter) 
after calibration with 200, 500, and 1000 nm beads (Polysciences).
Monocyte studies. Monocytes (purity >95%) were purified from 
buffy coats of HD and from patients’ PBMCs by sorting with anti-
CD14+ beads (MACS, Miltenyi Biotech) according to the manufactur-
er’s instructions. For the generation of EV-MDSCs, CD14+ cells (0.3 
× 106 in 300 μl) were cocultured with melanoma EVs (50 μg) in com-
plete medium supplemented with 10% EV-depleted FCS for 24 hours. 
For the transfection of miR inhibitors or miR mimics (QIAGEN), 50 
nM oligos in HiPerfect transfection reagent (QIAGEN) were admixed 
with monocytes or melanoma cells for 4 hours before the addition of 
FCS-containing medium. For miR inhibition in melanoma cells, EVs 
were isolated from CM 3 days after transfection with inhibitors, as 
described above. For proliferation studies, human T cells were stained 
with CFSE (Thermo Fisher Scientific) prior to stimulation with anti-
CD3 and anti-CD3/CD28 mAbs and assessed by flow cytometry after 
3 days. Cytokines were assessed in cell-free supernatants from cul-
tures of EV-MDSCs and from melanoma patients’ CD14+ cells purified 
from PBMCs using a Cytokine Bead Array (CBA) (BD Biosciences), 
according to the manufacturer’s instructions.
RNA extraction and qPCR analysis. RNA was extracted from 
monocytes, EV-MDSCs, melanoma cells, and melanoma specimens 
with the mirVana miRNA Isolation Kit (Ambion). qPCR analysis was 
performed according to the manufacturer’s instructions using Ther-
mo Fisher Scientific and Exiqon reagents to evaluate gene and miR 
expression levels, respectively. The list of assays is provided in Supple-
mental Table 8. The endogenous controls used for normalization were 
GAPDH and ACTB for genes and U6 snRNA and SNORD48 for miRs. 
qPCR was carried out in triplicate and run on the ABI Prism 7900HT 
instrument, and analysis was performed using SDS software, version 
2.2.2. Relative expression was determined using the 2-ΔCt method 
and expressed in arbitrary units, and FC was calculated by the 2-ΔΔCt 
method. For plasma and EV samples, synthetic spike-in ath-miR-159a 
was added to monitor RNA isolation efficiency, and the NucleoSpin 
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